Neil Slaven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neil Slaven has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Balázs Győrffy
Semmelweis University
202 shared publications - Diana Ivanoiu
Department of Surgery and Cancer, Imperial College London, London, United Kingdom. 2
202 shared publications - Eleonora Canale
Department of Surgery and Cancer, Imperial College London, London, United Kingdom. 2
202 shared publications - Giancarlo Pruneri
Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
202 shared publications - Iros Barozzi
Center for Cancer Research, Medical University of Vienna, Vienna, Austria
202 shared publications - Luca Magnani
Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK
202 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Table S5: SIDP results in MCF7 grown in white media (-E2). S5.1-5: the tables follow the same structure of S3.1-5.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Table S5: SIDP results in MCF7 grown in white media (-E2). S5.1-5: the tables follow the same structure of S3.1-5.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S15 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Figure S15. Validation of SIDP via chemical perturbation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S15 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Figure S15. Validation of SIDP via chemical perturbation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S17 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Table S17: Downstream analyses considering only the SIDV inferred genetic alterations with predicted impact on function and stratifying them by cancer-cell fraction (CCF) increase and decrease in metastatic samples. S17.1: summary of the results of the statistical tests performed to identify differences in the predicted impact of mutations stratified by change in CCF in metastatic samples compared to matched primary. The fraction of variants predicted as pathogenic and either showing an increase or a decrease in CCF (+- 0.1) was compared to that of those showing no change. P-values for the indicated features are shown (Chi-squared test). S17.2: similarly, the distribution of the predicted molecular effects of variants in the three groups (increase, decrease or no change in CCF) were compared using the Kruskal-Wallis test. S17.3: like S13.3 but testing for the enrichment of mutations with both computationally predicted pathogenic effects and a certain CCF increase or decrease in metastatic samples, that also show a certain behavior in SIDP.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S17 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Table S17: Downstream analyses considering only the SIDV inferred genetic alterations with predicted impact on function and stratifying them by cancer-cell fraction (CCF) increase and decrease in metastatic samples. S17.1: summary of the results of the statistical tests performed to identify differences in the predicted impact of mutations stratified by change in CCF in metastatic samples compared to matched primary. The fraction of variants predicted as pathogenic and either showing an increase or a decrease in CCF (+- 0.1) was compared to that of those showing no change. P-values for the indicated features are shown (Chi-squared test). S17.2: similarly, the distribution of the predicted molecular effects of variants in the three groups (increase, decrease or no change in CCF) were compared using the Kruskal-Wallis test. S17.3: like S13.3 but testing for the enrichment of mutations with both computationally predicted pathogenic effects and a certain CCF increase or decrease in metastatic samples, that also show a certain behavior in SIDP.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Figure 6. SIDP results are consistent across ER+ BC cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Figure 6. SIDP results are consistent across ER+ BC cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Table S10: Metadata of the clinical cohort profiled by SIDV. S10.1: for each donor, from which genetic material from matched normal, primary, and metastatic samples were derived, the following information is provided: the identifier for the samples; the center where the samples were collected; the sequencing batch; the age of diagnosis; the clinical features of the primary tumors; the indication of the metastatic sites. Legend: ER = estrogen-receptor alpha; PR = progesterone receptor; pct = percentage; HR = hormone therapy. S10.2: for each triplet of matched normal, primary and metastasis derived material, and separately for each one of the 100 donors, sequencing statistics are provided. Sequencing depth, fraction of the reads mapping to oligo baits, mean coverage on baits and corresponding fold-enrichment, and on-target mean coverage, are shown. The percentages (pct) of targeted bases covered at least 10x, 30x, 50x or 100x are also indicates.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Table S10: Metadata of the clinical cohort profiled by SIDV. S10.1: for each donor, from which genetic material from matched normal, primary, and metastatic samples were derived, the following information is provided: the identifier for the samples; the center where the samples were collected; the sequencing batch; the age of diagnosis; the clinical features of the primary tumors; the indication of the metastatic sites. Legend: ER = estrogen-receptor alpha; PR = progesterone receptor; pct = percentage; HR = hormone therapy. S10.2: for each triplet of matched normal, primary and metastasis derived material, and separately for each one of the 100 donors, sequencing statistics are provided. Sequencing depth, fraction of the reads mapping to oligo baits, mean coverage on baits and corresponding fold-enrichment, and on-target mean coverage, are shown. The percentages (pct) of targeted bases covered at least 10x, 30x, 50x or 100x are also indicates.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S18 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Figure 18. SIDV design and results.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S18 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Figure 18. SIDV design and results.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S18 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Table S18: Estimation of excess of mutations in the hormone-receptor positive breast cancer cohorts from the Hartwig Medical Foundation (HMF). The table lists, for each one of the regions showing an excess of functional alterations in the SIDV cohort (highlighted in table S13.1) the number of mutations in the region in both the SIDV and HMF cohort, along with the estimated background probability of seeing a mutation for the regions (using the HMF cohort) and the corresponding, empirical p-value of seeing the observed number of mutations, given the background probability (see Methods).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S18 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Table S18: Estimation of excess of mutations in the hormone-receptor positive breast cancer cohorts from the Hartwig Medical Foundation (HMF). The table lists, for each one of the regions showing an excess of functional alterations in the SIDV cohort (highlighted in table S13.1) the number of mutations in the region in both the SIDV and HMF cohort, along with the estimated background probability of seeing a mutation for the regions (using the HMF cohort) and the corresponding, empirical p-value of seeing the observed number of mutations, given the background probability (see Methods).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Figure 11. Validation of DF and IF SIDP hits.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Figure 11. Validation of DF and IF SIDP hits.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S19 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Figure 19. SIDV functional analyses.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S19 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Figure 19. SIDV functional analyses.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Figure 3. Estrogen deprivation in MCF7 cells introduce stochastic selective pressure in long-term CRISPRi screens.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution
Supplementary Figure 3. Estrogen deprivation in MCF7 cells introduce stochastic selective pressure in long-term CRISPRi screens.